Efficacy and Tolerance of Intensity Modulated Radiation Therapy for Skull Base Meningioma.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
13
01
2019
revised:
06
07
2019
accepted:
11
07
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
2
11
2019
Statut:
epublish
Résumé
The purpose of this study was to evaluate the efficacy and tolerance of normofractionated stereotactic radiation therapy (RT) and intensity modulated RT with helical tomotherapy for skull base meningioma. Between January 2009 and 2014, 46 patients with skull base meningioma were treated with normofractionated intensity modulated RT in stereotactic conditions (50%) or with helical tomotherapy (50%). Most of the lesions were localized in the cavernous sinus (59%). The mean planning target volume was 47.2 mL (range, 1.1-223 mL). After treatment, 5 lesions exhibited a partial response radiologically and 39 lesions were stable. At the time of treatment, 35 patients were symptomatic with a mean of 2 symptoms per patient. The most frequent symptoms were visual impairment (41%), cranial nerve dysfunction (20%), and headache (16%). The median follow-up time was 42 months (range, 10-76 months). After RT, 71% of patients exhibited an improvement of at least 1 symptom with a median interval of 15.6 months (range, 5.3-30.5 months). The most frequent improved symptoms were cranial nerve deficits (47%), visual impairment (45%), and headache (42%).The clinical response was correlated with the clinical target volume (CTV) margin ( RT for skull base meningiomas is an effective and safe treatment, leading in most cases to clinical improvement. The addition of a CTV margin to meningioma volume improved the symptoms of patients.
Identifiants
pubmed: 31673652
doi: 10.1016/j.adro.2019.07.009
pii: S2452-1094(19)30094-6
pmc: PMC6817551
doi:
Types de publication
Journal Article
Langues
eng
Pagination
587-595Informations de copyright
© 2019 The Author(s).
Références
J Neurooncol. 1996 Sep;29(3):197-205
pubmed: 8858525
Neurosurgery. 2013 Sep;73(3):401-10
pubmed: 23719052
Med Phys. 2010 Mar;37(3):1350-9
pubmed: 20384272
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63
pubmed: 17379447
Cancer Radiother. 2013 Oct;17(5-6):434-43
pubmed: 24011792
Cancer Radiother. 2001 Jun;5(3):217-36
pubmed: 11446076
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31
pubmed: 16029803
Cancer Radiother. 2012 Sep;16(5-6):410-7
pubmed: 22921979
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Radiother Oncol. 2005 Jan;74(1):49-52
pubmed: 15683669
Tumori. 2011 Jul-Aug;97(4):484-91
pubmed: 21989438
Radiother Oncol. 2008 Dec;89(3):254-62
pubmed: 18760851
World Neurosurg. 2016 May;89:620-627.e2
pubmed: 26704204
Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):967-75
pubmed: 9392533
Med Dosim. 2008 Autumn;33(3):239-47
pubmed: 18674690
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70
pubmed: 12128128
Strahlenther Onkol. 2006 Nov;182(11):635-40
pubmed: 17072520
Med Dosim. 2011 Winter;36(4):416-22
pubmed: 21397487
Radiother Oncol. 2013 Nov;109(2):330-4
pubmed: 24183065
Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72
pubmed: 12527049
Radiother Oncol. 2006 Aug;80(2):268-73
pubmed: 16890315
Acta Neurochir (Wien). 2015 Sep;157(9):1559-64
pubmed: 26231629
Clin Oncol (R Coll Radiol). 2010 Apr;22(3):179-84
pubmed: 20171061
Neurosurgery. 1995 Jul;37(1):1-9; discussion 9-10
pubmed: 8587667
Cancer Radiother. 2011 Jul;15(4):287-93
pubmed: 21664852
Neurosurgery. 1996 Nov;39(5):915-9; discussion 919-20
pubmed: 8905745
Neurosurgery. 2001 Feb;48(2):285-94; discussion 294-6
pubmed: 11220370
J Neurosurg. 2007 Nov;107(5):937-44
pubmed: 17977264
Neurosurgery. 2005 Nov;57(5):873-86; discussion 873-86
pubmed: 16284558
J Neurooncol. 2010 Jun;98(2):195-202
pubmed: 20405308
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):756-64
pubmed: 21345610
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):836-43
pubmed: 20133076
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11
pubmed: 15093905
World Neurosurg. 2014 Dec;82(6):1264-70
pubmed: 23994071
Radiat Oncol. 2014 Jan 17;9:27
pubmed: 24438670
Cancer Radiother. 2001 Oct;5(5):581-96
pubmed: 11715310
J Neurooncol. 2009 May;92(3):307-16
pubmed: 19357958
Radiother Oncol. 2006 Mar;78(3):313-21
pubmed: 16490269
Radiat Oncol. 2011 Apr 12;6:36
pubmed: 21486436
J Neurosurg. 2016 Aug;125(2):378-92
pubmed: 26745483
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1436-41
pubmed: 20971572
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):580-92
pubmed: 12957272
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1012-7
pubmed: 19117697
Radiother Oncol. 2013 Feb;106(2):186-91
pubmed: 22906549
Radiat Oncol. 2012 Dec 28;7:225
pubmed: 23270432
Neurosurgery. 2009 Jun;64(6):1090-9; discussion 1099-101
pubmed: 19487888
Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9
pubmed: 20305491
J Neurosurg. 2013 Sep;119(3):675-82
pubmed: 23808540
Surg Neurol. 2006 Jan;65(1):28-33; discussion 33-4
pubmed: 16378847